TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 14749208

Group type: EXPERIMENTAL
Intervention: Nicotinic acid (NA) ingestion to suppress adipose tissue lipolysis
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control (CON) without nicotinic acid ingestion
Number of subjects: 7
Study: 11203912

Group type: EXPERIMENTAL
Intervention: Alkaline, salt‐containing toothpaste
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Toothgel of similar contents
Number of subjects: 115

Group type: COMPARATOR
Intervention: Conventional toothpaste
Number of subjects: 115
Study: 9071101

Group type: EXPERIMENTAL
Intervention: Propofol (2.5 mg.kg‐1) with fentanyl (0.2 microgram.kg‐1)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Midazolam (0.2 mg.kg‐1) with fentanyl (0.2 microgram.kg‐1)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Thiopental (5 mg.kg‐1) with fentanyl (0.2 microgram.kg‐1)
Number of subjects: 90
Study: 8347901

Group type: EXPERIMENTAL
Intervention: Pharmacist intervention at clinic A
Number of subjects: 0

Group type: COMPARATOR
Intervention: No pharmacist intervention at clinic B
Number of subjects: 0
Study: 2939943

Group type: EXPERIMENTAL
Intervention: Oral medroxyprogesterone acetate (MPA) 300 mg three times daily
Number of subjects: 129

Group type: COMPARATOR
Intervention: Tamoxifen (TAM) 20 mg twice daily
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Oral medroxyprogesterone acetate (MPA)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Tamoxifen (TAM)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Oral medroxyprogesterone acetate (MPA) after cross-over
Number of subjects: 129

Group type: COMPARATOR
Intervention: Tamoxifen (TAM) after cross-over
Number of subjects: 129
Study: 31391104

Group type: EXPERIMENTAL
Intervention: Electroacupuncture plus warm needling therapy (treatment group)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Waitlist (control group)
Number of subjects: 80
Study: 27774726

Group type: EXPERIMENTAL
Intervention: Fiix-prothrombin time (Fiix-PT)
Number of subjects: 66

Group type: COMPARATOR
Intervention: PT-prothrombin time (PT)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Fiix-INR
Number of subjects: 66

Group type: COMPARATOR
Intervention: PT-INR
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: FII and FX activity
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: FII and FX
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: FVII
Number of subjects: 66
Study: 26409399

Group type: EXPERIMENTAL
Intervention: Structured, progressive, physiologically based, nurse-supervised, in-home exercise program (24 sessions over 12 weeks) targeting flexibility, strength, balance, endurance, and upper-limb function.
Number of subjects: 134

Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 134
Study: 22382203

Group type: EXPERIMENTAL
Intervention: Cranberry juice (CJ) - double-strength Ocean Spray light CJ (2 × 230 ml) daily for 4 months
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study: 21457292

Group type: COMPARATOR
Intervention: Care relationship mutuality
Number of subjects: 91
Study: 18516002

Group type: EXPERIMENTAL
Intervention: PPI group (pantoprazole 40 mg IV for 3 days, then 40 mg oral for 11 days)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group (intravenous and oral placebo)
Number of subjects: 47
Study: 16242376

Group type: EXPERIMENTAL
Intervention: Injection of hypertonic saline into the lumbar multifidus muscle
Number of subjects: 15

Group type: COMPARATOR
Intervention: Comparison with pain maps from L4 medial dorsal rami and L4-5 interspinous ligaments
Number of subjects: 15
Study: 12709008

Group type: EXPERIMENTAL
Intervention: Hydroquinone 4% cream
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Skin whitening complex 5% cream
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 30
Study: 10906303

Group type: EXPERIMENTAL
Intervention: Conservative treatment of small AAAs
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Screening for AAAs
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Surgery after conservative treatment
Number of subjects: 127

Group type: COMPARATOR
Intervention: Control group (non-screened)
Number of subjects: 127
Study: 8811148

Group type: EXPERIMENTAL
Intervention: Backrest elevation at 0 degrees
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Backrest elevation at 30 degrees
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Backrest elevation at 45 degrees
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Mechanical ventilation and vasoactive drugs
Number of subjects: 39
Study: 1420754

Group type: EXPERIMENTAL
Intervention: Balsalazide 3 g/day
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Balsalazide 6 g/day
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Balsalazide (both doses)
Number of subjects: 108
Study: 4059802

Group type: EXPERIMENTAL
Intervention: Topical budesonide
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 29985668

Group type: EXPERIMENTAL
Intervention: Estonia‐specific optimized speech stimuli for Nasometer II
Number of subjects: 106

Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 106
Study: 27983774

Group type: EXPERIMENTAL
Intervention: Indwelling pleural catheter (IPC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Talc pleurodesis
Number of subjects: 0
Study: 25998922

Group type: EXPERIMENTAL
Intervention: EHR‐linked mailings (automated)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Automated plus telephone assistance (assisted)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Automated and assisted plus nurse navigation (navigated)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 24565347

Group type: EXPERIMENTAL
Intervention: Intrathecal morphine 50 μg
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Intrathecal morphine 100 μg
Number of subjects: 123

Group type: COMPARATOR
Intervention: Both groups (50 μg and 100 μg)
Number of subjects: 123
Study: 22029878

Group type: EXPERIMENTAL
Intervention: Integrated services delivery (ISD) network
Number of subjects: 100

Group type: COMPARATOR
Intervention: No integrated services delivery (ISD) network
Number of subjects: 100
Study: 19235523

Group type: EXPERIMENTAL
Intervention: Reciprocal learning setting with role switching and role definition
Number of subjects: 72

Group type: COMPARATOR
Intervention: Reciprocal learning settings without role switching and role definition
Number of subjects: 72
Study: 16751657

Group type: EXPERIMENTAL
Intervention: Vitamin K1 10 mg per day for 2-7 days (Group A)
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Dexamethasone 10 mg per day for 1 day (Group B)
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Dexamethasone 10 mg per day for 2 days (Group C)
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Dexamethasone 10 mg per day for 1 day and Vitamin K1 10 mg per day for 2-7 days (Group D)
Number of subjects: 280

Group type: COMPARATOR
Intervention: No treatment (Control group)
Number of subjects: 280
Study: 15632893

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/day (aggressive lipid lowering)
Number of subjects: 893

Group type: COMPARATOR
Intervention: Pravastatin 40 mg/day (moderate lipid lowering)
Number of subjects: 893
Study: 11287512

Group type: EXPERIMENTAL
Intervention: Sonographically guided PTC (12 procedures)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Fluoroscopically guided PTC (12 procedures)
Number of subjects: 19
Study: 9390367

Group type: EXPERIMENTAL
Intervention: Eyesys videokeratoscope (windows workstation: version 2000 W)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Topcon Autokeratometer (KR 3500)
Number of subjects: 20
Study: 15374306

Group type: EXPERIMENTAL
Intervention: Pramiracetam (600 mg twice a day)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 3266276

Group type: EXPERIMENTAL
Intervention: Above- and below-lesion EMG control of functional electrical stimulation (FES)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Below-lesion response-EMG
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Above-lesion EMG
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Below-lesion EMG
Number of subjects: 0
Study: 30273282

Group type: EXPERIMENTAL
Intervention: Compression Garments (CG)
Number of subjects: 10
Study: 31667790

Group type: EXPERIMENTAL
Intervention: Risankizumab 150 mg subcutaneous dose
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Risankizumab 75 mg subcutaneous dose
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Risankizumab (both doses)
Number of subjects: 225
Study: 29924331

Group type: EXPERIMENTAL
Intervention: Higher plasma selenium concentrations (second tertile)
Number of subjects: 1727

Group type: EXPERIMENTAL
Intervention: Higher plasma selenium concentrations (third tertile)
Number of subjects: 1727

Group type: EXPERIMENTAL
Intervention: Highest tertile of plasma selenium and highest category of intake of β‐cryptoxanthin
Number of subjects: 1727

Group type: EXPERIMENTAL
Intervention: Highest tertile of plasma selenium and highest category of intake of lycopene
Number of subjects: 1727
Study: 27581470

Group type: COMPARATOR
Intervention: Bar15/0LS (mean ± SEM), 169 ± 14
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control2, 164 ± 20
Number of subjects: 12

Group type: COMPARATOR
Intervention: Bar15/0, 144 ± 15
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control1, 140 ± 17
Number of subjects: 12

Group type: COMPARATOR
Intervention: Bar10/5, 117 ± 12
Number of subjects: 12

Group type: COMPARATOR
Intervention: Bar15/5, 116 ± 9
Number of subjects: 12

Group type: COMPARATOR
Intervention: Bar10/10, 100 ± 9
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Higher protein content
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: All 5 RS-containing bars
Number of subjects: 12
Study: 25177815

Group type: EXPERIMENTAL
Intervention: Meldonium administered at a dose of 1000 mg/ml intravenously in addition to controlled physical training (CPT) with intensity 80% for 2 weeks (10 SFI)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Meldonium group
Number of subjects: 35
Study: 22920930

Group type: EXPERIMENTAL
Intervention: Prasugrel (10 mg daily)
Number of subjects: 9326

Group type: COMPARATOR
Intervention: Clopidogrel (75 mg daily)
Number of subjects: 9326

Group type: EXPERIMENTAL
Intervention: Prasugrel (5 mg daily)
Number of subjects: 9326
Study: 20921542

Group type: EXPERIMENTAL
Intervention: 14 days of moderate caloric restriction with 8.5 hours of nighttime sleep opportunity
Number of subjects: 10

Group type: COMPARATOR
Intervention: 14 days of moderate caloric restriction with 5.5 hours of nighttime sleep opportunity
Number of subjects: 10
Study: 18754820

Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg ketamine
Number of subjects: 63

Group type: COMPARATOR
Intervention: 1.5 mcg/kg fentanyl
Number of subjects: 63
Study: 16129547

Group type: EXPERIMENTAL
Intervention: Intravaginal misoprostol (50 microg four times with 4h intervals)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Oxytocin infusion (starting from 2 mIU/min, increasing every 30 min with 2 mIU/min increments up to 40 mIU/min)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Intravaginal misoprostol
Number of subjects: 64

Group type: COMPARATOR
Intervention: Oxytocin infusion
Number of subjects: 64
Study: 12828699

Group type: EXPERIMENTAL
Intervention: Nail-splinting technique with splint removal after 3 days (Group 1)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Nail-splinting technique with splint removal after 2 weeks (Group 2)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Nail-splinting technique (both groups)
Number of subjects: 57
Study: 11069379

Group type: EXPERIMENTAL
Intervention: Papaverine injection
Number of subjects: 28

Group type: COMPARATOR
Intervention: Needle puncture alone
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Internal spermatic vein measurement
Number of subjects: 28
Study: 8804093

Group type: EXPERIMENTAL
Intervention: Identification task (reporting orientation of the oblique line)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Easy localisation task (indicating left or right side of the display)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Difficult localisation task (indicating upper or lower part of the display)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Left vs right localisation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Up vs down localisation
Number of subjects: 0
Study: 1299504

Group type: EXPERIMENTAL
Intervention: 200 micrograms/day chromium picolinate (CrPic)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 59
Study: 6432374

Group type: EXPERIMENTAL
Intervention: Prolonged physical exercise with calorie deficiency and sleep deprivation
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Prolonged physical exercise with calorie deficiency
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Prolonged physical exercise and calorie deficiency
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sleep deprivation
Number of subjects: 24
Study: 30565407

Group type: EXPERIMENTAL
Intervention: BioChaperone insulin Lispro (BCLIS)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Insulin aspart (ASP)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Faster insulin aspart (FIA)
Number of subjects: 43
Study: 29770541

Group type: EXPERIMENTAL
Intervention: sitagliptin 50 mg qd
Number of subjects: 53

Group type: COMPARATOR
Intervention: glibenclamide 2.5 mg per day
Number of subjects: 53
Study: 27015624

Group type: EXPERIMENTAL
Intervention: Tramadol (1 mg/kg with 100 mL normal saline)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Paracetamol (1 g intravenously)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Dexketoprofen (50 mg intravenously)
Number of subjects: 90
Study: 24224787

Group type: EXPERIMENTAL
Intervention: Peer-led self-management programme (six 2-hour sessions)
Number of subjects: 242
Study: 22205604

Group type: EXPERIMENTAL
Intervention: Progressive Addition Lenses (PALs)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Single Vision Lenses (SVLs)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Single Vision Lenses (SVLs) after PALs
Number of subjects: 85
Study: 21257441

Group type: EXPERIMENTAL
Intervention: Monepantel, administered orally at a minimum dose of 2.5 mg/kg bodyweight
Number of subjects: 0

Group type: COMPARATOR
Intervention: Untreated control sheep
Number of subjects: 0
Study: 18498921

Group type: EXPERIMENTAL
Intervention: Doripenem 500 mg q8h i.v. (4-hour infusion)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Imipenem 500 mg q6h (30-minute infusion) or 1000 mg q8h i.v. (1-hour infusion)
Number of subjects: 0
Study: 16122453

Group type: EXPERIMENTAL
Intervention: Cognitive domain summary scores based on precedence
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Cognitive domain summary scores based on principal components analysis
Number of subjects: 204

Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 204
Study: 12686280

Group type: EXPERIMENTAL
Intervention: 3 hours time in bed
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: 5 hours time in bed
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: 7 hours time in bed
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: 9 hours time in bed
Number of subjects: 66
Study: 10584839

Group type: EXPERIMENTAL
Intervention: Fludrocortisone 0.3 mg/day
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no fludrocortisone)
Number of subjects: 30
Study: 8965976

Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ) 2 x 200 mg daily
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sodium Valproate (VPA) 2 x 300 mg daily
Number of subjects: 60
Study: 1871175

Group type: EXPERIMENTAL
Intervention: Evening primrose oil (EPO) for 10 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Safflower oil (SFO) for 10 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Paraffin for 10 days
Number of subjects: 0
Study: 2998219

Group type: EXPERIMENTAL
Intervention: Low dose fentanyl anaesthesia (0.01 mg/kg bw) - Group A
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: High dose fentanyl anaesthesia (0.035 mg/kg bw) - Group B
Number of subjects: 32
Study: 30817438

Group type: EXPERIMENTAL
Intervention: Lidocaine 2% with adrenaline
Number of subjects: 9

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 9
Study: 29987324

Group type: COMPARATOR
Intervention: EHR‐alone group
Number of subjects: 794

Group type: COMPARATOR
Intervention: EHR plus education group
Number of subjects: 794

Group type: COMPARATOR
Intervention: EHR tools alone and EHR plus education interventions
Number of subjects: 794
Study: 27211040

Group type: EXPERIMENTAL
Intervention: Microbead array (MBA) assay with a cut-off of 500
Number of subjects: 133

Group type: COMPARATOR
Intervention: Hemagglutination inhibition assay (HAI)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Microbead array (MBA) assay with a cut-off of 500 for A/Brisbane strain
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Microbead array (MBA) assay with a cut-off of 500 for B/Florida strain
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Overall results from both studies
Number of subjects: 133
Study: 24880194

Group type: EXPERIMENTAL
Intervention: Ultrasonographically guided axillary nerve block (ANB) combined with suprascapular nerve block (SSNB) using 10 mL ropivacaine
Number of subjects: 42

Group type: COMPARATOR
Intervention: Suprascapular nerve block (SSNB) with 10 mL 0.75% ropivacaine and axillary nerve block (ANB) with 10 mL saline
Number of subjects: 42
Study: 22414839

Group type: EXPERIMENTAL
Intervention: SpiraPost (group A; DMG, Englewood, NJ)
Number of subjects: 40

Group type: COMPARATOR
Intervention: DT Light‐Post Illusion X‐RO (group B; Bisco Inc, Schaumburg, IL)
Number of subjects: 40
Study: 20448192

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) injection
Number of subjects: 100

Group type: COMPARATOR
Intervention: Corticosteroid injection
Number of subjects: 100
Study: 22301207

Group type: EXPERIMENTAL
Intervention: IV lidocaine (0.5, 1.0, or 1.5 mg/kg) with midazolam (0.03 mg/kg)
Number of subjects: 96

Group type: COMPARATOR
Intervention: IV lidocaine (0.5, 1.0, or 1.5 mg/kg) with placebo
Number of subjects: 96
Study: 15556966

Group type: EXPERIMENTAL
Intervention: Sevoflurane preconditioning (10 min at 4 vol%)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Sevoflurane preconditioning
Number of subjects: 72
Study: 12466788

Group type: EXPERIMENTAL
Intervention: High-dose dipyridamole infusion (0.70 mg/kg) followed by technetium 99m tetrofosmin (TF) injection (74 to 370 MBq)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Control group (20 age-matched patients without heart disease)
Number of subjects: 106
Study: 9568451

Group type: EXPERIMENTAL
Intervention: Physical training (16 weeks)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Physical training (6 weeks)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Cycle ergometer with calisthenic exercises
Number of subjects: 134

Group type: COMPARATOR
Intervention: Cycle ergometer alone
Number of subjects: 134
Study: 7855555

Group type: EXPERIMENTAL
Intervention: Cefpodoxime proxetil (CP) 8 mg/kg/d b.i.d.
Number of subjects: 260

Group type: COMPARATOR
Intervention: Amoxicillin/clavulanic acid (ACA) 40/10 mg/kg/d t.i.d.
Number of subjects: 260
Study: 2642671

Group type: EXPERIMENTAL
Intervention: Physical exercise training for six months
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo therapy for six months
Number of subjects: 16
Study: 4908340

Group type: EXPERIMENTAL
Intervention: Aerosol administration of influenza vaccine
Number of subjects: 2100

Group type: EXPERIMENTAL
Intervention: Subcutaneous administration of A2/Hong Kong/68 virus vaccine
Number of subjects: 2100

Group type: EXPERIMENTAL
Intervention: Bivalent (A2 and B) influenza virus vaccine
Number of subjects: 2100

Group type: EXPERIMENTAL
Intervention: Single-dose immunization
Number of subjects: 2100

Group type: EXPERIMENTAL
Intervention: 2-dose immunization
Number of subjects: 2100

Group type: EXPERIMENTAL
Intervention: Cigarette smoking
Number of subjects: 2100
Study: 29239901

Group type: EXPERIMENTAL
Intervention: Maternal antiretroviral therapy (mART)
Number of subjects: 2431

Group type: COMPARATOR
Intervention: Infant nevirapine (iNVP) prophylaxis
Number of subjects: 2431

Group type: EXPERIMENTAL
Intervention: mART
Number of subjects: 2431

Group type: COMPARATOR
Intervention: iNVP
Number of subjects: 2431
Study: 27981743

Group type: EXPERIMENTAL
Intervention: Whey protein isolate (WPI) 50 g
Number of subjects: 56

Group type: COMPARATOR
Intervention: Soy protein isolate (SPI) 50 g
Number of subjects: 56
Study: 25311146

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.3 μg.kg(‐1)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Propofol 1 mg.kg(‐1)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Saline 0.9% (control)
Number of subjects: 120
Study: 24024321

Group type: EXPERIMENTAL
Intervention: Acupuncture at Hegu (LI 4)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (routine oocyte retrieval)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo group (placebo needles)
Number of subjects: 90
Study: 21444712

Group type: EXPERIMENTAL
Intervention: FV-100 100 mg once daily (QD) for 7 days
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: FV-100 200 mg QD for 7 days
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: FV-100 400 mg QD for 7 days
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: FV-100 400 mg twice a day for 7 days
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: FV-100 800 mg QD for 7 days
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Single 400 mg dose of FV-100
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: 400 mg QD dosing regimen for 7 days in elderly subjects
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: FV-100 (all doses)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: High-fat meal effect on FV-100
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: FV-100
Number of subjects: 59
Study: 18192843

Group type: EXPERIMENTAL
Intervention: 2 mg nicotine tabs
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 16455186

Group type: EXPERIMENTAL
Intervention: Diclofenac 50 mg enteric‐coated tablet
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 12802644

Group type: EXPERIMENTAL
Intervention: 2 g of cefotaxime (Group A)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Isotonic sodium chloride solution (Group B)
Number of subjects: 92